Event Date: May 05, 2022



Related Resources l Recording

No new medication for Alzheimer Disease and dementia  (other than treatments for the behavioural problems) has been approved in Canada in twenty years. We will review where we are now - medications with modest effects for cognitive symptoms and behavioural and psychological problems. We will look at where we want to be with curative and preventative treatments, and examine how we may get to those goals in the next decade.
 
This integrated KTE webinar event is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium of Neurodegeneration in Aging (CCNA). 

                                

Presenter(s):

Chertkow-Howard-3.jpg

Howard Chertkow, MD, FRCP, FCAHS

Dr. Chertkow is a cognitive neurologist and director of the new Kimel Central for Brain Health at the Baycrest Health Sciences  Centre. He is also Senior Scientist and Chair in Cognitive Neurology and Innovation at Baycrest’s Rotman Research Institute and a Professor in the Dept. of Medicine (Neurology) at University of Toronto. His major areas of research interest include early diagnosis of Alzheimer’s Disease, and therapy of dementia using neuromodulation approaches such as transcranial direct current stimulation. Dr. Chertkow is Scientific Director for the Canadian Consortium on Neurodegeneration in Aging (CCNA), a national organization established by the Canadian government via CIHR and partners.